This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Circulating Anti-Beta2-glycoprotein Antibodies and Endothelial Dysfunction

Sponsored by Hospital Universitario Getafe

About this trial

Last updated 13 years ago

Study ID

ABGPINO150613

Status

Completed

Type

Observational

Placebo

No

Accepting

18 to 90 Years
Male

Trial Timing

Ended 14 years ago

What is this trial about?

Circulating anti-beta2-glycoprotein antibodies have been associated with coronary artery disease and peripheral arterial disease. This auto-antibodies could activate endothelial cells leading to the expression of leukocyte adhesion molecules and increasing the release of pro-inflammatory cytokines. On the other hand, endothelial dysfunction of atherosclerotic patients acts as a primary pathogenic event, as it occur before structural changes are evident on angiogram or ultrasound scan. Loss of endothelial normal function causes vasoconstriction, local coagulation alterations and an increase arterial wall proliferation. This situation s been attributed to a reduction in nitric oxide bioactivity, and to an increase oxygen-free radical formation in the context of the pro-inflammatory status found in atherosclerosis. Hypothesis: Circulating Anti-beta2-glycoprotein I antibodies could be associated with endothelial dysfunction and nitric oxide metabolism disruption en patients with peripheral arterial disease.

What are the participation requirements?

Inclusion Criteria

* Male gender

* Peripheral arterial disease diagnosis

* Intermittent claudication.

* Hemodynamic confirmation of the disease through non-invasive vascular studies.

Exclusion Criteria

* Autoimmune disease

* Previous revascularization of the ischemic limb.

* Ischemic ulcers

* Previous history of organ transplants.

* Treatment with immunosuppressors